Optical Sensors Receives FDA Marketing Clearance for Its Model 2000 CapnoProbe(TM) Instrument

Company Receives Substantial Equivalence Status for Miniaturized Instrument



Apr 18, 2001, 01:00 ET from Optical Sensors Incorporated

    MINNEAPOLIS, April 18 /PRNewswire/ --
     Optical Sensors Inc. (OTC Bulletin Board:   OPSI) announced today that it
 received clearance from the U.S. Food and Drug Administration (FDA) to market
 a miniaturized version of its CapnoProbe Instrument (the Model 2000).  With
 its proprietary CapnoProbe Sensor, this instrument provides a measurement of
 sublingual CO2 levels.  Tissue CO2 as measured with the CapnoProbe Sensor
 correlates with other more invasive and costly indicators of a patient's
 changing condition.  Clinical studies indicate that rapidly deployable, early
 perfusion indicators may allow quicker, more effective intervention by medical
 personnel in life critical situations.  The original concept for this medical
 breakthrough came from the Institute of Critical Care Medicine (ICCM) and Dr.
 Max Harry Weil, President.  ICCM is a non-profit, internationally recognized
 research and education leader in critical care medicine for over 40 years.
     The CapnoProbe Sensor Model 2000 System reduces the size of the CapnoProbe
 instrument from a bench top instrument to a hand-held battery operated
 instrument.  Paulita LaPlante, President and Chief Executive Officer, said,
 "The reduced size of the instrument configuration allows practical application
 of this important technology in more hectic environments such as emergency and
 operating rooms.  Healthcare professionals can monitor multiple patients CO2
 levels much more easily, similar to the manner in which temperature levels are
 currently taken with a portable instrument and disposable sensor."  Ms.
 LaPlante also commented that, "OSI is holding discussions with several
 potential distribution partners for the CapnoProbe sensor.  The approval of a
 smaller CapnoProbe sensor system increases the value of the product since this
 initial commercial configuration more closely approximates similar
 non-invasive technologies that are being used in the hospital marketplace.
 Additionally, we appreciate having another successful application with the FDA
 since we intend to further miniaturize this technology in support of
 respiratory and cardiac projects being investigated at ICCM. "
     Optical Sensors Incorporated (OSI) is a technology development company
 specializing in low-cost, fiber optic sensors and instruments.  OSI's mission
 is to leverage its proprietary sensor platform technology into innovative and
 low cost applications for minimally-to-less invasive medical diagnostic and
 management products.  OSI is the developer of the CapnoProbe SL sensor system
 for the measurement of sublingual CO2, an on-demand patient monitoring system,
 and the SensiCath sensor system for the measurement of blood pH, CO2 and O2,
 an on-demand blood gas monitoring system.
     The Institute of Critical Care Medicine, located in Palm Springs, Calif.,
 is a non-profit research and educational center which brings together a
 multidisciplinary team of professionals to collaborate with clinical and
 research centers worldwide.  Their chief areas of expertise include acute
 cardiorespiratory crises with special focus on circulatory shock and
 cardiopulmonary arrest.  Visit the ICCM web site at http://www.911research.org
     For more information about OSI technology and services, see the company's
 web site at http://www.opsi.com
 
     Except for historical information contained herein, the disclosures in
 this news release are forward-looking statements which could be affected by
 certain risks and uncertainties, including:  successful development and market
 acceptance of the CapnoProbe sensor; actions taken and alternative products
 introduced or marketed by the Company's competitors; and actions related to
 regulatory matters.  These risks are described in more detail in the Company's
 Annual Report on Form 10-K for the year ended Dec. 31, 2000.
 
 

SOURCE Optical Sensors Incorporated
    MINNEAPOLIS, April 18 /PRNewswire/ --
     Optical Sensors Inc. (OTC Bulletin Board:   OPSI) announced today that it
 received clearance from the U.S. Food and Drug Administration (FDA) to market
 a miniaturized version of its CapnoProbe Instrument (the Model 2000).  With
 its proprietary CapnoProbe Sensor, this instrument provides a measurement of
 sublingual CO2 levels.  Tissue CO2 as measured with the CapnoProbe Sensor
 correlates with other more invasive and costly indicators of a patient's
 changing condition.  Clinical studies indicate that rapidly deployable, early
 perfusion indicators may allow quicker, more effective intervention by medical
 personnel in life critical situations.  The original concept for this medical
 breakthrough came from the Institute of Critical Care Medicine (ICCM) and Dr.
 Max Harry Weil, President.  ICCM is a non-profit, internationally recognized
 research and education leader in critical care medicine for over 40 years.
     The CapnoProbe Sensor Model 2000 System reduces the size of the CapnoProbe
 instrument from a bench top instrument to a hand-held battery operated
 instrument.  Paulita LaPlante, President and Chief Executive Officer, said,
 "The reduced size of the instrument configuration allows practical application
 of this important technology in more hectic environments such as emergency and
 operating rooms.  Healthcare professionals can monitor multiple patients CO2
 levels much more easily, similar to the manner in which temperature levels are
 currently taken with a portable instrument and disposable sensor."  Ms.
 LaPlante also commented that, "OSI is holding discussions with several
 potential distribution partners for the CapnoProbe sensor.  The approval of a
 smaller CapnoProbe sensor system increases the value of the product since this
 initial commercial configuration more closely approximates similar
 non-invasive technologies that are being used in the hospital marketplace.
 Additionally, we appreciate having another successful application with the FDA
 since we intend to further miniaturize this technology in support of
 respiratory and cardiac projects being investigated at ICCM. "
     Optical Sensors Incorporated (OSI) is a technology development company
 specializing in low-cost, fiber optic sensors and instruments.  OSI's mission
 is to leverage its proprietary sensor platform technology into innovative and
 low cost applications for minimally-to-less invasive medical diagnostic and
 management products.  OSI is the developer of the CapnoProbe SL sensor system
 for the measurement of sublingual CO2, an on-demand patient monitoring system,
 and the SensiCath sensor system for the measurement of blood pH, CO2 and O2,
 an on-demand blood gas monitoring system.
     The Institute of Critical Care Medicine, located in Palm Springs, Calif.,
 is a non-profit research and educational center which brings together a
 multidisciplinary team of professionals to collaborate with clinical and
 research centers worldwide.  Their chief areas of expertise include acute
 cardiorespiratory crises with special focus on circulatory shock and
 cardiopulmonary arrest.  Visit the ICCM web site at http://www.911research.org
     For more information about OSI technology and services, see the company's
 web site at http://www.opsi.com
 
     Except for historical information contained herein, the disclosures in
 this news release are forward-looking statements which could be affected by
 certain risks and uncertainties, including:  successful development and market
 acceptance of the CapnoProbe sensor; actions taken and alternative products
 introduced or marketed by the Company's competitors; and actions related to
 regulatory matters.  These risks are described in more detail in the Company's
 Annual Report on Form 10-K for the year ended Dec. 31, 2000.
 
 SOURCE  Optical Sensors Incorporated